The causal relationship of liver disease to neuropathy has been questioned. This study was designed to evaluate the incidence and character of peripheral neuropathy in patients with liver cirrhosis.

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Some diseases producing liver dysfunction can independently cause peripheral neuropathy. Hence, a cause and effect relationship between liver disease and neuropathy has been questioned.

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. - Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. QUTENZA (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...